Advertisement

Family Firm Innovation in the Global Pharmaceutical Industry

  • Alessandra PerriEmail author
  • Enzo Peruffo
Chapter
First Online:
  • 416 Downloads

Abstract

This chapter describes the global pharmaceutical industry, focusing on its most important characteristics and competitive dynamics. Several features of this industry question the fit of families as an adequate ownership and governance category. This chapter devotes special attention to analyzing the role of innovation, in reference to established literature that has extensively investigated the most important technological trajectories and discontinuities that characterize the industry’s evolution, and focuses on the most recent technological dynamics and current organization of innovative activities. Finally, a dedicated focus on the Italian context helps illustrate the country-level environmental conditions that shape the conduct of Italian family firms, as analyzed in Chap.  5.

Keywords

Global pharmaceutical industry Innovation process Italian pharmaceutical industry 
This is a preview of subscription content, log in to check access.

References

  1. Arora, A., & Gambardella, A. (1990). Complementarity and external linkages: The strategies of the large firms in biotechnology. The Journal of Industrial Economics, 38(4), 361–379.Google Scholar
  2. Bierly, P., & Chakrabarti, A. (1996). Generic knowledge strategies in the U.S. pharmaceutical industry. Strategic Management Journal, 17, 123–135.CrossRefGoogle Scholar
  3. Bogner, W. C., & Thomas, H. (1994). Core competence and competitive advantage: A model and illustrative evidence from the pharmaceutical industry. In G. Hamel & A. Heene (Eds.), Competence based competition. Chichester: Wiley.Google Scholar
  4. Bottazzi, G., Dosi, G., Lippi, M., Pammolli, F., & Riccaboni, M. (2001). Innovation and corporate growth in the evolution of the drug industry. International Journal of Industrial Organization, 19, 1161–1187.CrossRefGoogle Scholar
  5. Bruche, G. (2012). Emerging Indian pharma multinationals: Latecomer catch-up strategies in a globalised high-tech industry. European Journal of International Management, 6, 300–322.CrossRefGoogle Scholar
  6. Brusoni, S., & Geuna, A. (2003). An international comparison of sectoral knowledge bases: Persistence and integration in the pharmaceutical industry. Research Policy, 32(10), 1897–1912.CrossRefGoogle Scholar
  7. Brusoni, S., Criscuolo, P., & Geuna, A. (2005). The knowledge bases of the world’s largest pharmaceutical groups: what do patent citations to non-patent literature reveal?. Economics of Innovation and New Technology, 14(5), 395–415.Google Scholar
  8. Challu, P. (1995). Effects of the monopolistic patenting of medicine in Italy since 1978. International Journal of Technology Management, 10(2–3), 237–252.Google Scholar
  9. Chandy, R., Hopstaken, B., Narasimhan, O., & Prabhu, J. (2006). From invention to innovation: Conversion ability in product development. Journal of Marketing Research, 43, 494–508.CrossRefGoogle Scholar
  10. Cockburn, I. M. (2004). The changing structure of the pharmaceutical industry. Health Affairs, 23, 10–22.CrossRefGoogle Scholar
  11. Cockburn, I. M. (2006). Is the pharmaceutical industry in a productivity crisis? Innovation Policy and the Economy, 7, 1–32.CrossRefGoogle Scholar
  12. Cockburn, I. M., & Henderson, R. M. (2000). Publicly funded science and the productivity of the pharmaceutical industry. Innovation Policy and the Economy, 1, 1–34.CrossRefGoogle Scholar
  13. Cool, K., & Schendel, D. (1987). Strategic group formation and performance: The case of the U.S. pharmaceutical industry. Management Science, 33, 1102–1124.Google Scholar
  14. DeCarolis, D. M. (2003). Competencies and imitability in the pharmaceutical industry: An analysis of their relationship with firm performance. Journal of Management, 29, 27–50.CrossRefGoogle Scholar
  15. DiMasi, J., Hansen, R., Grabowski, H., & Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10, 107–142.CrossRefGoogle Scholar
  16. DiMasi, J. A., & Faden, L. B. (2011). Competitiveness in follow-on drug R&D: A race or imitation? Nature Reviews Drug Discovery, 10(1), 23–27.CrossRefGoogle Scholar
  17. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22(2), 151–185.CrossRefGoogle Scholar
  18. DiMasi, J. A., & Paquette, C. (2004). The economics of follow-on drug research and development: Trends in entry rates and the timing of development. Pharmacoeconomics, 22, 1–14.CrossRefGoogle Scholar
  19. Faini, R., & Schiantarelli, F. (1983). Regional implications of industrial policy: The Italian case. Journal of Public Policy, 3(1), 97–117.CrossRefGoogle Scholar
  20. FARMINDUSTRIA. (2016). Rapporto sulle biotecnologie del settore farmaceutico in Italia, available at: www.farmindustria.it.
  21. Fernández, Z., & Nieto, M. J. (2005). Internationalization strategy of small and medium-sized family businesses: Some influential factors. Family Business Review, 18(1), 77–89.CrossRefGoogle Scholar
  22. Frezza, L. (2015). Business. Scienza e Farmaci. L’industria del farmaco: Aboutbooks.Google Scholar
  23. Gamba, S. (2016). The effect of intellectual property rights on domestic innovation in the pharmaceutical sector. Bruno Kessler Foundation: Research Institute for the Evaluation of Public Policies.Google Scholar
  24. Gambardella, A. (1995). Science and innovation: The US pharmaceutical industry in the 1980s. Cambridge, MA: Cambridge University Press.CrossRefGoogle Scholar
  25. Gambardella, A., Orsenigo, L., & Pammolli, F. (2000). Global competitiveness in pharmaceuticals: A European perspective, MPRA Paper No. 15965.Google Scholar
  26. Ghemawat, P. (2010). Strategy and the business landscape. Upper Saddle River, NJ: Pearson.Google Scholar
  27. Gómez-Mejía, L. R., Haynes, K. T., Núñez-Nickel, M., Jacobson, K. J., & Moyano-Fuentes, J. (2007). Socioemotional wealth and business risks in family-controlled firms: Evidence from Spanish olive oil mills. Administrative Science Quarterly, 52(1), 106–137.CrossRefGoogle Scholar
  28. Grabowski, H. G., Kyle, M., Mortimer, R., Long, G., & Kirson, N. (2011). Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Health Affairs, 30(11), 2157–2166.CrossRefGoogle Scholar
  29. Grabowski, H. G., & Vernon, J. M. (1987). Pioneers, imitators, and generics—A simulation model of schumpeterian competition. The Quarterly Journal of Economics, 102(3), 491–525.CrossRefGoogle Scholar
  30. Grewal, R., Chakravarty, A., Ding, M., & Liechty, J. (2008). Counting chickens before the eggs hatch: Associating new product development portfolios with shareholder expectations in the pharmaceutical sector. International Journal of Research in Marketing, 25, 261–272.CrossRefGoogle Scholar
  31. Griliches, Z., & Cockburn, I. (1994). Generics and new goods in pharmaceutical price indexes. American Economic Review, 84(5), 1213–1232.Google Scholar
  32. Henderson, R., & Cockburn, I. (1994). Measuring competence? Exploring firm effects in pharmaceutical research, Strategic Management Journal, 15, 63–84.Google Scholar
  33. Henderson, R., & Cockburn, I. (1996). Scale, scope and spillovers: The determinants of research productivity in drug discovery. Rand Journal of Economics, 27(1), 32–59.CrossRefGoogle Scholar
  34. Hill, C., & Hansen, G. (1991). A longitudinal study of the cause and consequences of changes in diversification in the U.S. pharmaceutical industry 1977–1986. Strategic Management Journal, 12, 187–199.CrossRefGoogle Scholar
  35. KPMG. (2011). China’s pharmaceutical industry! Poised for the giant leap. Beijing: KPMG Advisory China Limited.Google Scholar
  36. Levin, R. C., Klevorick, A. K., Nelson, R. R., Winter, S. G., Gilbert, R., & Griliches, Z. (1987). Appropriating the returns from industrial research and development. Brookings Papers on Economic Activity, 3, 783–831.CrossRefGoogle Scholar
  37. MARKETLINE. (2015). Industrie farmaceutiche italiane, available at: http://www.marketline.com
  38. Orsenigo, L. (1989). The emergence of biotechnology: institutions and markets in industrial innovation. London: Pinter Publishers Ltd.Google Scholar
  39. Orsenigo, L., Pammolli, F., & Riccaboni, M. (2001). Technological change and network dynamics: Lessons from the pharmaceutical industry. Research Policy, 30(3), 485–508.CrossRefGoogle Scholar
  40. Perugini, M. (2015). Il farsi di una grande impresa. Franco Angeli Storia: La Montecatini fra le due guerre mondiali.Google Scholar
  41. Petrova, E. (2014). Innovation in the pharmaceutical industry: The process of drug discovery and development. In Innovation and marketing in the pharmaceutical industry (pp. 19–81). New York: Springer.Google Scholar
  42. Pisano, G. (1994). Knowledge integration and the locus of learning: An empirical analysis of process development. Strategic Management Journal, 15, 85–100.CrossRefGoogle Scholar
  43. Powell, W. W., Koput, K. W., & Smith-Doerr, L. (1996). Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology, Administrative Science Quarterly, 41(1), 116–145.Google Scholar
  44. Reiffen, D., & Ward, M. R. (2005). Generic drug industry dynamics. Review of Economics and Statistics, 87(1), 37–49.CrossRefGoogle Scholar
  45. Roberts, P. W. (1999). Product innovation, product-market competition, and persistent profit- ability in the U.S. pharmaceutical industry. Strategic Management Journal, 20, 655–670.CrossRefGoogle Scholar
  46. Scalera, V. G., Perri, A., & Mudambi, R. (2015). Managing innovation in emerging economies: Organizational arrangements and resources of foreign MNEs in the Chinese pharmaceutical industry. In Emerging Economies and Multinational Enterprises (pp. 201–233). Bingley: Emerald Group Publishing Limited.Google Scholar
  47. Scherer, F., & Weisburst, S. (1995). Economic effects of strengthening pharmaceutical patent protection in Italy. International Review of Industrial Property and Copyright Law, 26, 1009–1024.Google Scholar
  48. Sharma, A., & Lacey, N. (2004). Linking product development outcomes to market valuation of the firm: The case of the US pharmaceutical industry. Journal of Product Innovation Management, 21, 297–308.CrossRefGoogle Scholar
  49. Stremersch, S., & Lemmens, A. (2009). Sales growth of new pharmaceuticals across the globe: The role of regulatory regimes. Marketing Science, 28(4), 690–708.CrossRefGoogle Scholar
  50. The Economist. (2012). Battling borderless bugs. http://www.economist.com/node/21542410. Accessed 7 Jan 2014.
  51. Thomas, L. G. (1990). Regulation and firm size: FDA impacts on innovation. Rand Journal of Economics, 21, 497–517.CrossRefGoogle Scholar
  52. Wuyts, S., & Dutta, S. (2008). Licensing exchange—Insights from the biopharmaceutical industry. International Journal of Research in Marketing, 25(4), 273–281.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2017

Authors and Affiliations

  1. 1.Department of ManagementCa’ Foscari UniversityVeniceItaly
  2. 2.Department of Business and ManagementLUISS Guido CarliRomeItaly

Personalised recommendations

Cite chapter

Buy options